Concerning the risk for worsening HF event, SGLT-2 inhibitor treatment was shown not to affect the corresponding risk among individuals hospitalized with acute or recently decompensated HF (RR = 0.69, 95% CI; 0.43–1.10, I2 = 31%), as shown in Figure 3a. This evidence concerns the gene SLC5A2 and hydrops fetalis.